Explore every episode of the podcast GHAPPcast

Amy Stewart, ARNP, from Capital Digestive Care, explains the role of the IL-23/IL-17 axis in inflammatory bowel disease (IBD). Learn how these cytokines drive chronic inflammation and their significance in IBD pathogenesis, as well as how targeted therapies address these pathways.

In this video, Erica Heagy, NP, from Alaska Digestive and Liver Disease, discusses the IL-23/IL-17 axis and its role in inflammatory bowel disease (IBD) and other immune-mediated conditions. Learn how the IL-23 cytokine promotes differentiation of CD4+ T cells into Th17 cells, stimulating the production of IL-17A, IL-17F, TNF, and IL-6. This pathway is critical in diseases like psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and axial spondyloarthritis. Targeting IL-23 or IL-17 represents a promising therapeutic approach for these conditions.

Join Gabriella McCardy, NP, and guest Ali Crentes, NP, as they dive into the IL-23/IL-17 axis and its critical role in inflammatory bowel disease (IBD). This episode explores the pathogenesis of IBD, targeted therapies, and practical approaches to patient care. Gain insights into how understanding these pathways can improve outcomes and inform shared decision-making.

Discover the science behind Guselkumab and its role in treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, explains the mechanism of action of Guselkumab.

Discover the key differences between humoral and cell-mediated immunity in this FAQ video module featuring Erica Heagy, NP. Learn how these adaptive immune responses work, what they target, and their roles in defending against pathogens. For more insights, visit the GHAPP Digital Hub!

Check out this GHAPPcast episode on CSID from the 2024 GHAPP National Conference with Daksesh Patel, D.O., Kaitlin Colella, PA, and Kate Scarlata, MPH, RD. 

In part three of this miniseries, Elizabeth Goacher, NP, Jeremy Davis, NP, and Allison Moser, NP, discuss key takeaways from the GHAPP National Conference 2024 on Primary Biliary Cholangitis (PBC). They emphasize the shift toward more stringent treatment goals, including the normalization of alkaline phosphatase and bilirubin levels. This new approach marks a significant change from previous guidelines, with the aim of achieving better patient outcomes. The panel reflects on how these advancements will impact PBC management and looks forward to more progress at GHAPP 2025.

This podcast is supported by an unrestricted educational grant from Gilead Sciences.

In part two of this podcast miniseries, Elizabeth Goacher, NP, Jeremy Davis, NP, and Allison Moser, NP, dive into new therapeutics in the treatment of Primary Biliary Cholangitis (PBC). The panel discusses emerging medications and their dual impact on disease management and symptom relief, including pruritus. Stay tuned for part three for more insights into PBC advancements!

This podcast is supported by an unrestricted educational grant from Gilead Sciences.

In this three-part miniseries, Elizabeth Goacher, NP, Jeremy Davis, NP, and Allison Moser, NP, discuss emerging treatments for Primary Biliary Cholangitis (PBC). In today's episode, they explore the increasing prevalence, awareness, and identification of PBC, highlighting recent developments in treatment options. The panel reflects on their experiences from the GHAPP 2024 meeting, sharing insights into how enhanced identification and liver disease awareness are driving changes in clinical practice. Go listen to parts 2 & 3!

This podcast is supported by an unrestricted educational grant from Gilead Sciences.

In this KOL Conversation, Renee Pozza, NP,  and Allysa Saggese, NP, explore the impact of newly FDA-approved therapies for Primary Biliary Cholangitis (PBC). They highlight the exciting potential of these treatments to improve symptom management, particularly pruritus, while offering enhanced safety profiles and greater flexibility in patient care.

This insightful exchange reflects the evolving landscape of liver disease management and offers valuable perspectives for healthcare providers.

In this KOL conversation, Jordan Mayberry, PA-C, from UT Southwestern Medical Center, shares insights on managing pruritus in patients with Primary Biliary Cholangitis (PBC). Mayberry discusses the challenges of pruritus as a side effect and the excitement around new, emerging therapies that offer improved management options. He encourages providers to screen for PBC in patients experiencing pruritus now that these treatments are available.

Thank you to Madrigal for sponsoring this Medication Review Video Module!

In this GHAPP Medication Review Video Module, nurse practitioner Whitney Steinmetz discusses the clinical profile of Resmetirom, a thyroid hormone receptor beta agonist indicated for adults with metabolic-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. Whitney explores the mechanism of action, dosage recommendations, and the dual primary endpoint success of Resmetirom in clinical trials. She highlights key considerations, including drug interactions and common side effects such as nausea and diarrhea, and how they are generally well-tolerated over time. Learn more about Resmetirom's impact on liver health and patient care by visiting the GHAPP website or app.

Thank you to Madrigal for sponsoring the Medication Review Video Module.

In this GHAPP Medication Review video, Robin Soto, a board-certified nurse practitioner at UC San Diego Health Hepatology, explains the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of MASH in adults with mild to moderate fibrosis (F2-F3). Robin describes how Resmetirom, a liver-directed, thyroid hormone receptor beta agonist, targets liver fat accumulation, promoting fatty acid oxidation and improving cholesterol metabolism. She highlights its anti-inflammatory effects and ability to reduce liver fibrosis by selectively activating receptors in the liver, while minimizing systemic side effects. For more information, visit the GHAPP website and ACE app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Jonathan Yeh, a physician assistant at the Center for Liver Disease and Transplantation at Columbia University Irving Medical Center, discusses advancements in diagnosing and staging metabolic dysfunction-associated steatohepatitis (MASH). He explains the transition from traditional liver biopsy to non-invasive testing methods such as FibroScan and the Enhanced Liver Fibrosis (ELF) test for assessing fibrosis stages. Jonathan highlights the use of these methods, in combination with blood tests, to provide reliable staging of fibrosis in patients with MASH. For more information, visit the GHAPP website or ACE app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, shares insights on the consequences of untreated metabolic-associated steatohepatitis (MASH) and the importance of early intervention. She discusses how MASH can silently progress to liver failure, liver cancer, and increase cardiovascular risks. Corrie provides valuable strategies for advanced practice providers (APPs) to educate patients, focusing on simplifying complex information, promoting lifestyle changes, and emphasizing the benefits of early intervention. For more information on MASH, visit the GHAPP website or app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, explains the liver condition known as MASH, or metabolic dysfunction-associated steatohepatitis, which was previously referred to as NASH. She describes MASH as an inflammatory liver disease caused by excess fat buildup in the liver and its close connection to metabolic issues like obesity, type 2 diabetes, and dyslipidemia. Corrie also discusses the significance of the name change from NASH to MASH, highlighting the shift toward recognizing metabolic health as a key factor in managing the disease. For more information, visit the GHAPP website or app.

Thank you to Madrigal for sponsoring this Journal Club Video Module!

In this GHAPP Journal Club review, Lisa Richards, a board-certified family nurse practitioner specializing in hepatology at UC San Diego Health, presents pivotal research from a February 2024 New England Journal of Medicine publication. The phase 3 randomized controlled trial evaluated the efficacy of Resmineron, the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Lisa discusses key findings from the study, including improvements in liver fibrosis and NASH resolution in patients treated with Resmineron compared to placebo. Join her for an in-depth look at this groundbreaking therapy and its impact on patient care.

Thank you to Madrigal for sponsoring this episode of GHAPPcast.

In this episode of GHAPPcast, nurse practitioners Patrick Horne  and April Morris from discuss the complexities of identifying and managing patients with metabolic-associated steatohepatitis (MASH). They explore clinical approaches, including the use of bloodwork, family history, and advanced diagnostic tools such as FibroScan, to recognize patients at risk. Patrick and April emphasize the importance of lifestyle interventions like diet and exercise alongside new medical therapies, while also offering practical tips for clinicians on patient monitoring and treatment management. Tune in for valuable insights into managing MASH in clinical practice.

Thank you to Ardelyx for sponsoring this FAQ Video Module! 

Kim Orleck, GHAPP member and a Physician Assistant at Atlanta Gastroenterology Associates. In this FAQ, Kim shares some of the best practices for accelerating the process of finding the right therapy for IBS-C patients. She emphasizes the importance of using a positive diagnostic strategy to confidently diagnose IBS-C, reducing unnecessary tests, financial strain, and the time to treatment. Kim also discusses the significance of setting appropriate timelines, involving patients in therapy decisions, and considering factors like dosing, side effects, and cost to optimize treatment outcomes. For more details, visit ghapp.org.

Thank you to Ardelyx for sponsoring this GHAPPcast episode! 

In this episode of GHAPPcast, Christina Hanson & Kim Kearns, both seasoned GI & hepatology experts, dive into the pathophysiology, neuromodulation, and patient-centered care for IBS-C (Irritable Bowel Syndrome with Constipation). They discuss the gut-brain interaction and provide practical insights on how to manage IBS-C effectively. From patient education to overcoming common challenges in treatment, this episode equips APPs with the tools needed to empower both themselves and their patients. Tune in for expert advice and strategies to enhance your practice and patient care.

Thank you to Ardelyx for sponsoring this FAQ Video Module! 

Join Kim Orleck, GHAPP member and a practicing Physician Assistant at Atlanta Gastroenterology Associates, on this FAQ video module! Kim shares insights on best practices for determining a clinically meaningful response to therapy for patients with IBS-C. She emphasizes the importance of setting realistic goals, understanding patient symptoms, and using open-ended questions to ensure comprehensive care. Kim also discusses the significance of focusing on the most bothersome symptoms and ensuring that patients are aware of all available therapeutic options. For more details, visit ghapp.org.

Thank you to Ardelyx for sponsoring this FAQ Video Module! 

Join Kim Orleck, GHAPP member, and a Physician Assistant at Atlanta Gastroenterology Associates. In this FAQ, Kim discusses the key resources she uses to stay informed on the latest approaches to managing IBS-C patients. She highlights the importance of guidelines from the ACG and AGA, attending conferences like the GHAPP National Conference and ACG Conference, and utilizing industry partners and pharmaceutical reps for the latest data and coverage options. Kim also emphasizes the value of peer-to-peer discussions for continuous learning in the field. For more information, visit ghapp.org.

In this video, Tedra Gray, a Nurse Practitioner, explains what it means for a biosimilar to be interchangeable and why it’s important.

In this episode of GHAPPcast, host Gabriella McCarty, Nurse Practitioner, is joined by special guest Emily, a patient who shares her firsthand experience with biosimilars.

Listen as they explore the real-world impact of biosimilars, from initial concerns to achieving remission. This episode provides valuable insights into patient perspectives and the role of advanced practice providers in facilitating smooth transitions.

Thank you to Ardelyx for sponsoring this GHAPPcast episode! 

In this episode of GHAPPcast, host Christina Hanson, FNP, alongside guest Kim Orleck, PA-C, dives into advanced strategies for diagnosing and managing IBS-C. They discuss the importance of the positive diagnostic strategy, ways to differentiate IBS-C from other conditions, and share valuable insights on how to optimize patient care and treatment. Listeners will gain practical tips for effectively communicating with patients, setting realistic expectations, and making informed decisions on therapeutic options. Tune in to enhance your approach to managing IBS-C and stay up-to-date with the latest in GI and hepatology care. Don't forget to subscribe and visit GHAPP's website for more resources!

Join Nurse Practitioner Tedra Gray as she explains the key differences between biosimilars and generics in gastroenterology.

Thank you to Ardelyx for sponsoring this FAQ Video Module! 

Join Kim Orleck, GHAPP member and Physician Assistant at Atlanta Gastroenterology Associates. In this FAQ, Kim discusses how new mechanisms of action influence her prescribing decisions for IBS-C therapy. She highlights the exciting introduction of a novel medication with a triple-action mechanism of action, which offers an alternative to the traditional secretagogues. Kim explains how this new therapy works by inhibiting the sodium-hydrogen exchanger, leading to increased luminal water content, reduced intestinal permeability, and decreased visceral hypersensitivity, ultimately addressing the multifactorial pathophysiology of IBS-C. For more information, visit ghapp.org.

In this episode of GHAPPcast, host Gabriella McCarty, a Nurse Practitioner, is joined by fellow Nurse Practitioner Tedra Gray. They delve into the world of biosimilars, focusing on empowering Advanced Practice Providers (APPs) for better patient conversations.

Listen in as they discuss the role of APPs in patient education, strategies for overcoming challenges with biosimilars, and how to effectively communicate the benefits to patients.

Join Dr. Nadege Gunn, from the 2024 Liver Connect Conference. In this special episode, she is joined by Elizabeth Coacher, PA, and Ann Moore, FNP, to discuss the management of NASH (Nonalcoholic Steatohepatitis), newly approved treatments, and the importance of clinical trials.

They explore patient-centered care, lifestyle modifications, and non-invasive tests for identifying at-risk patients. Tune in for insights on balancing clinical trial participation with approved therapies, addressing patient access and equity, and the need for ongoing education in hepatology. This episode offers valuable information for healthcare providers committed to improving liver health. Don't miss this engaging and informative discussion!

Hosted by: Nadege Gunn, MD
With Special Guests: Elizabeth Goacher, PA, and Ann Moore, NP

In our twelfth and final episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP, and guest Jamie Brogan, NP have an in-depth conversation about discussing biosimilars with patients.

The learning objectives for this episode are to:

• Design methods to appropriately explain biosimilars to patients
• Address potential patient perceptions of biosimilars
• Devise methods to combat the nocebo effect when discussing biosimilars with patients
• Explain the potential benefits of biosimilars for patients

Please take our evaluation regarding this podcast here:   https://www.ghapp.org/biosimilars-podcast-eval

Welcome to our eleventh episode of the GHAPP & RhAPP biosimilar podcast series! In the penultimate episode host Amanda Mixon, PA-C has an in-depth conversation with the incredible Naomi A. Amudala, CRNP, MSN,  about The Nocebo Effect.

The learning objectives and goals for this episode are to:

• Define the nocebo effect
• Appraise nocebo effect research as it pertains to biosimilars
• Explain effective ways to counter the nocebo effect such as patient counseling

Please take our evaluation regarding this podcast here:  https://www.ghapp.org/biosimilars-podcast-eval

In the tenth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP-C, and guest Sharon Dudley-Brown PHD, FNP-BC, FAAN, FAANP discuss the practical use of biosimilars in Gastroenterology APP practice.

The learning objectives for this episode are to:

• Interpret the AGA Biosimilars Roundtable meeting report and the Crohn’s & Colitis Foundation Biosimilar position statement
• Discuss the use of biosimilars in the treatment of gastrointestinal diseases
• Produce strategies for implementing the use of biosimilars in gastroenterology practice

Please take our evaluation regarding this podcast here:   https://www.ghapp.org/biosimilars-podcast-eval

In the ninth episode of the GHAPP & RhAPP biosimilar podcast series host Amanda Mixon, PA-C, and guest Daric Mueller, PA-C discuss the practical use of biosimilars in rheumatology APP practice.

The learning objectives for this episode are to:

• Interpret the ACR white paper on biosimilars in rheumatology
• Discuss the use of biosimilars in the treatment of rheumatic diseases
• Produce strategies for implementing the use of biosimilars in rheumatology practice

Please take our evaluation regarding this podcast here:   https://www.ghapp.org/biosimilars-podcast-eval

In our eighth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP, and guest Gwen Cassidy, NP review the benefits of biosimilars.

The learning objectives for this episode are to:

• Outline the cost savings of biosimilars for patients
• Summarize the cost savings for healthcare organizations
• Discuss  healthcare providers  feeling the pressure and burden of rising costs and how biosimilars may help in bridging the transition from volume-based to value-based care

Please take our evaluation regarding this podcast here:   https://www.ghapp.org/biosimilars-podcast-eval

In the seventh episode of the GHAPP & RhAPP biosimilar podcast series host Amanda Mixon, PA-C, and guest Audrey Gibson, PA-C discuss the interplay between managed care and biosimilars.

The learning objectives for this episode are to:

• Discuss managed care implications for biosimilars reaching the market
• Identify the benefits of biosimilars in managed care
• Formulate strategies managed care professionals can employ to establish clinical pathways and increase biosimilar uptake in practice

Please take our evaluation regarding this podcast here:   https://www.ghapp.org/biosimilars-podcast-eval

For our sixth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP-C, and guest Janette Villalon, NP discuss interchangeability & switching of biosimilars.

The learning objectives and goals for this episode are to:
-Define interchangeability
-Illustrate the required info for a biosimilar to be deemed interchangeable by the FDA
-Recognize how interchangeability studies are conducted
-Analyze what interchangeability and switching mean for:
     -APPs
     -Pharmacists
     -Patients

Please take our evaluation regarding this podcast here: https://www.ghapp.org/biosimilars-podcast-eval

In the fifth episode of the GHAPP & RhAPP biosimilar podcast series host Amanda Mixon, PA-C, and guest Betsy Kirchner, DNP review the important concept of biosimilar extrapolation.

The learning objectives for this episode are to:

• Define extrapolation
• Understand why extrapolation is important.
• Understand the key aspects that may be considered for scientific justification of extrapolation including:
         -MOA in each condition
         -Pharmacokinetics and biodistribution
         -Expected toxicities
         -Other- concomitant medications/comorbidities

Please take our evaluation regarding this podcast here: https://www.ghapp.org/biosimilars-podcast-eval

In the fourth episode of the GHAPP & RhAPP biosimilar podcast series host Gabriella McCarty, NP  and guest Tedra Gray, NP discuss the differences between biosimilars and generic drugs.

The learning objectives and goals for this episode are to:
-Compare and contrast biosimilars and generics regarding:
         -Molecular size and structure
         -Complexity of development
         -Cost of development

Please take our evaluation regarding this podcast here: https://www.ghapp.org/biosimilars-podcast-eval

Welcome to our third episode of the GHAPP & RhAPP biosimilar podcast series! In this episode host Amanda Mixon, PA-C has an in-depth conversation with the incredible Danielle Gatti-Palumbo, PharmD, BCACP, AAHIVP,  about The Regulatory Pathway to Biosimilar Approval.

The learning objectives and goals for this episode are to:
-Summarize the totality of evidence approach to determining biosimilarity including:
      -Analytical testing for comparative structural and functional characterization
      -Nonclinical testing to evaluate the safety profile
      -Comparative human pharmacokinetic and pharmacodynamic studies
      -Immunogenicity Assessment
      -Comparative clinical studies if needed

Please take our evaluation regarding this podcast here:  https://www.ghapp.org/biosimilars-podcast-eval

Join us for our second episode of the GHAPP & RhAPP biosimilar podcast series! In this episode host Amanda Mixon, PA-C discusses the Development of Biosimilars with our esteemed guest Tanya Golovanoff, PharmD.

The learning objectives and goals for this episode are to:
-Distill the immense amount of research and development that occurs to develop biosimilars
-Articulate the biosimilar manufacturing process
-Explain how biosimilars are named

Please take our evaluation regarding this podcast here: https://www.ghapp.org/biosimilars-podcast-eval

Join us for the first episode of the GHAPP & RhAPP biosimilar podcast series! In this episode Gabriella McCarty, NP-C and Jennifer Geremia, PA-C discuss What Are Biosimilars?

The learning objectives and goals for this episode are to:
-Define biologic therapy
-Define biosimilars
-Define reference product
-Summarize the impact of The Biologics Price Competition and Innovation Act

Please take our evaluation regarding this podcast here: https://www.ghapp.org/biosimilars-podcast-eval